Juvenile Dermatomyositis Clinical Trial
— MYOCITOfficial title:
Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis
The MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with corticosteroids in new-onset patients with juvenile dermatomyositis (JDM) in a phase II trial with the objective to obtain a better efficacy than the conventional combination methotrexate (MTX) and corticosteroids over the 24 week study period. Thus, the investigators hypothesize that baricitinib could be used as a first line treatment in all forms of DMJ, including the most severe one, with a good safety profile.
Status | Recruiting |
Enrollment | 16 |
Est. completion date | September 2026 |
Est. primary completion date | May 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 18 Years |
Eligibility | Inclusion Criteria: - Patient aged 3-18 years with new-onset juvenile dermatomyositis, according to the ENMC 2018 dermatomyositis classification criteria - Muscle weakness at MMT and/or CMAS (MMT < 74 and/or CMAS < 45) - Seropositivity or vaccination for chickenpox - For patients of childbearing age (following menarche) : Negative ßHCG and effective method of contraception (sexual abstinence, hormonal contraception, intrauterine device or hormone-releasing system, cap, diaphragm or sponge with spermicide, condom) until the 7 days after administration of the last dose of Baricitinib - Informed consent form signed by the patient or child' s parents Patient affiliated to a social security regime Exclusion Criteria - Amyopathic dermatomyositis (without muscle weakness) - Inability to be treated by oral way or to take pills - Previous treatment with JAK inhibitor - Previous treatment of JDM with immunosuppressive drugs or biologics other than corticosteroids. Previous treatment with prednisone was allowed for no more than 1 month. - Previous history of cancer - Live vaccine within the 4 weeks before starting baricitinib therapy - Current, or recent (< 4 weeks prior to baseline) of active infections according to investigator appreciation, but necessarily, including HBV, HCV, HIV, tuberculosis. - Positive blood CMV PCR - Creatinine clearance < 40 ml/min - Lymphocytes < 0,5x109 cell/L and Neutrophils < 1x109 cell/L - Hemoglobin < 8 g/dL - Symptomatic herpes herpes simplex infection within 12 weeks prior to inclusion - History of thrombosis or considered at high risk of venous thrombosis by the investigator - Presence of severe JDM-related involvements: cardiovascular (requiring vasopressive drug and/or intensive care unit), respiratory (requiring oxygen and/or intensive care unit), gastrointestinal (requiring abdominal surgery). - History of severe non-related JDM involvement: cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological or neuropsychiatric disorders or any other serious and/or instable illness that, in the opinion of the investigator, could constitute an unacceptable risk, when taking baricitinib. - Actual or in project of pregrancy and breast-feeding until the 7 days after administration of the last dose of Baricitinib - Patient on AME (state medical aid) - Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Pellegrin | Bordeaux | |
France | Hôpital Femme Mère Enfant | Bron | |
France | Hôpital Jeanne de Flandre | Lille | |
France | Hôpital La Timone | Marseille | |
France | Hôpital Villeneuce | Montpellier | |
France | Hôpital Brabois | Nancy | |
France | Hôpital du Kremlin-Bicêtre | Paris | |
France | Hôpital Necker - Enfants malades : service de dermatologie | Paris | |
France | Hopital Necker - Enfants malades : unité d'immuno-hématologie et rhumatologie | Paris | |
France | Hôpital Robert Debré | Paris | |
France | Hôpital Trousseau | Paris | |
France | Hôpital de Hautepierre | Strasbourg | |
France | Hôpital Purpan | Toulouse |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003 Feb 15;49(1):7-15. doi: 10.1002/art.10924. — View Citation
Giancane G, Lavarello C, Pistorio A, Oliveira SK, Zulian F, Cuttica R, Fischbach M, Magnusson B, Pastore S, Marini R, Martino S, Pagnier A, Soler C, Stanevicha V, Ten Cate R, Uziel Y, Vojinovic J, Fueri E, Ravelli A, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. Pediatr Rheumatol Online J. 2019 May 22;17(1):24. doi: 10.1186/s12969-019-0326-5. — View Citation
Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013 May;72(5):686-93. doi: 10.1136/annrheumdis-2012-201483. Epub 2012 Jun 26. — View Citation
Mammen AL, Allenbach Y, Stenzel W, Benveniste O; ENMC 239th Workshop Study Group. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul Disord. 2020 Jan;30(1):70-92. doi: 10.1016/j.nmd.2019.10.005. Epub 2019 Oct 25. No abstract available. — View Citation
Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, Brunner J, Dannecker G, Silva CA, Stanevicha V, Cate RT, van Suijlekom-Smit LW, Voygioyka O, Fischbach M, Foeldvari I, Hilario O, Modesto C, Saurenmann RK, Sauvain MJ, Scheibel I, Sommelet D, Tambic-Bukovac L, Barcellona R, Brik R, Ehl S, Jovanovic M, Rovensky J, Bagnasco F, Lovell DJ, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008 Jan 15;59(1):4-13. doi: 10.1002/art.23248. — View Citation
Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994 Dec;37(12):1761-9. doi: 10.1002/art.1780371209. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PRINTO 20 (Paediatric Rheumatology INternational Trials Organisation scale) | Achievement of the validated juvenile dermatomyositis PRINTO 20 level of improvement. PRINTO 20 level of improvement is defined as a 20% or greater improvement in three or more of the six variables of the juvenile dermatomyositis core set, with one or no variable worsening by more than 30% (muscle strength can not be the variable worsening) :
muscle strength, assessed with the Childhood Myositis Assessment Scale (CMAS), physician's global assessment of the patient's disease activity (Physician's VAS) global disease activity assessment through the Disease Activity Score (DAS) functional ability through the Childhood Health Assessment Questionnaire (C-HAQ) parent's global assessment of the child's overall wellbeing (Parent's VAS) health-related quality of life, through the parent version of the Child Health Questionnaire (CHQ-Phs) A higher score is 100% and means a better outcome, a lower score is 0% and means a worse result. |
At week 24 | |
Secondary | PRINTO 20 Paediatric Rheumatology INternational Trials Organisation scale - level 20 | achievement of the validated juvenile dermatomyositis PRINTO 20 level ; reaching a minimum of 20 % a higher score is 100% and mean a better outcome a lower score is 0% and means a worse result | At week 4, 8, 12 and 16 | |
Secondary | PRINTO 50 Paediatric Rheumatology INternational Trials Organisation scale - level 50 | achievement of the validated juvenile dermatomyositis PRINTO 50 level ; reaching a minimum of 50 % a higher score is 100% and mean a better outcome a lower score is 0% and means a worse result | At week 4, 8, 12 and 16 | |
Secondary | PRINTO 70 Paediatric Rheumatology INternational Trials Organisation scale - level 70 | achievement of the validated juvenile dermatomyositis PRINTO 70 level ; reaching a minimum of 70 % a higher score is 100% and mean a better outcome a lower score is 0% and means a worse result | At week 4, 8, 12 and 16 | |
Secondary | PRINTO 90 Paediatric Rheumatology INternational Trials Organisation scale - level 90 | achievement of the validated juvenile dermatomyositis PRINTO 90 level ; reaching a minimum of 90 % a higher score is 100% and mean a better outcome a lower score is 0% and means a worse result | At week 4, 8, 12 and 16 | |
Secondary | Total Improvement Score (TIS) | Relative and absolute variations of TIS. The TIS is the sum of the improvement in each of the six core set measures of disease activits The minimum score is 0 (worse) and maximum score is 100 (better) A major response is defined by a score > 70 A moderate response is defined by a score > 45 A minimal response is defined by a score > 30 | At inclusion, weeks 4, 8, 12, 16 and 24 | |
Secondary | Clinically inactive disease | according to the PRINTO criteria | At weeks 4, 8, 12 and 24 | |
Secondary | Cutaneous Dermatomyositis Disease Area and Severity Index (CDSAI) | assess skin activity and damage across multiple body regions in patients with dermatomyositis | At inclusion, weeks 4, 8, 12, 16 and 24 | |
Secondary | Myositis Disease Activity Assessment VAS (MYOACT) | Assess Relative and absolute variations of extramuscular activity | At inclusion, weeks 4, 8, 12, 16 and 24 | |
Secondary | interstitial lung disease | Assessed by improvement of at least 10% of FCV, PTC, and DLCO and/or improvement of Lung tomodensitomery according to a specific scale | At inclusion and at week 24 | |
Secondary | Dose of corticosteroid | Dose tapering at 6 months | At week 24 | |
Secondary | Pharmacokinetics study | Non-compartmental analysis of baricitinib | At weeks 4, 8, 12, and 24 | |
Secondary | Pharmacokinetics (PK) study with area under the curve | Correlation between area under the curve AUC in ng.h/ml (PK parameter of baricitinib) and disease activity 's scores | At weeks 4, 8, 12, and 24 | |
Secondary | Pharmacokinetics (PK) study with maximal concentration | Correlation between maximal concentration Cmax in ng/mL (PK parameter of baricitinib) and disease activity 's scores | At weeks 4, 8, 12, and 24 | |
Secondary | Pharmacokinetics (PK) study with through concentration | Correlation between through concentration Ctrough, in ng/mL (PK parameter of baricitinib) and disease activity 's scores | At weeks 4, 8, 12, and 24 | |
Secondary | dosage of cytokines | Measurement of serum IFN -, IFN-?, IL-1ß, IL-4, Il-5, IL-6, IL-8, IL-10, IL-12p70, IL-22, TNF a | At inclusion, weeks 4 and 24 | |
Secondary | transcriptomic analysis | Study of genes expression within 800 genes related to immunity | At inclusion, weeks 4 and 24 | |
Secondary | Biopsy | Assessment of muscle biopsies according to the internationally validated score system | At inclusion, weeks 4 and 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
Recruiting |
NCT00059748 -
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
|
||
Completed |
NCT00323960 -
Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
|
Phase 3 | |
Completed |
NCT02267005 -
The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis
|
N/A | |
Completed |
NCT00106184 -
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
|
Phase 2 | |
Completed |
NCT02245841 -
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
|
Phase 4 | |
Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
Recruiting |
NCT01217320 -
Creatine Supplementation in Pediatric Rheumatology
|
N/A | |
Completed |
NCT05509140 -
Clinical Analysis of Juvenile Dermatomyositis Patients
|
||
Recruiting |
NCT01276470 -
Environmental Risk Factors for the Anti-synthetase Syndrome
|
||
Recruiting |
NCT03433638 -
Juvenile Dermatomyositis
|
N/A | |
Recruiting |
NCT03432455 -
Incidence and Prevalence of Juvenile Dermatomyositis
|
N/A | |
Completed |
NCT00815282 -
Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
|
Phase 4 | |
Completed |
NCT01697254 -
The CARRA Registry
|
N/A |